

09 September 2010

**Discontinuation of Alupent<sup>®</sup> Syrup (orciprenaline sulphate)  
September 2010**

Dear Healthcare Professional


You may recall that I wrote to you in October 2009 to inform you of the forthcoming discontinuation of Alupent<sup>®</sup> Syrup (orciprenaline sulphate). This is to inform you that the product will no longer be available from the end of September 2010.

The reason for this discontinuation is that other more selective  $\beta_2$  agonists are available.

This letter is intended to allow sufficient time for patients using Alupent Syrup to be transferred to alternative therapy.

Boehringer Ingelheim Ireland Limited sincerely regrets any inconvenience caused by this discontinuation. If you require further information, please contact Medical Information on 01 2959620 or [medinfo.dbl@boehringer-ingelheim.com](mailto:medinfo.dbl@boehringer-ingelheim.com).

Yours sincerely,



Ciarán McCarron  
Scientific Affairs Executive

Ciarán McCarron  
Telephone +353-1-2959620  
E-Mail [ciaran.mccarron@boehringer-ingelheim.com](mailto:ciaran.mccarron@boehringer-ingelheim.com)

Corrig Court  
Corrig Road  
Sandyford Business Estate  
Dublin 18  
Telephone +353-1-2959620  
Telefax +353-1-2959624  
[www.boehringer-ingelheim.ie](http://www.boehringer-ingelheim.ie)

Directors:  
Mr A Owenson (British)  
Chairman  
Dr J C Edwards (Irish)

Registered Office:  
Corrig Court  
Corrig Road  
Sandyford Business Estate  
Dublin 18

Registered in Ireland  
No. 316925